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Abstract This review provides an overview of direct and
indirect technologies to screen protein–ligand interactions
with mass spectrometry. These technologies have as a key
feature the selection or affinity purification of ligands in
mixtures prior to detection. Specific fields of interest for
these technologies are metabolic profiling of bioactive
metabolites, natural extract screening, and the screening of
libraries for bioactives, such as parallel synthesis libraries
and small combichem libraries. The review addresses the
principles of each of the methods discussed, with a focus on
developments in recent years, and the applicability of the
methods to lead generation and development in drug
discovery.
Keywords Mass spectrometry.Protein–ligand
interactions.Affinity.Bioassay.Pre- and on-column
mixture screening
Abbreviations
ACE affinity capillary electrophoresis
ALIS automated ligand identification system
CE capillary electrophoresis
FAC frontal affinity chromatography
FACE frontal analysis capillary electrophoresis
GPCR G-protein-coupled receptor
HPLC high-performance liquid chromatography
HSA human serum albumin
IAM immobilized artificial membrane
IMAC immobilized metal affinity chromatography
LC liquid chromatography
MS mass spectrometry
MALDI matrix-assisted laser desorption ionization
nAChR nicotinic acetylcholine receptor
SEC size-exclusion chromatography
SPR surface plasmon resonance
TOF time of flight
Introduction
The development of new lead compounds in drug discovery
has been of continuous importance over the past few
decades. However, high attrition rates and the decreasing
number of new drug approvals in the past few years have
increased the necessity for new development tools. Protein
affinity selection methods utilizing mass spectrometry (MS)
are among the more recently developed methods that can be
a valuable addition to traditional drug discovery techniques.
They distinguish themselves by utilizing the very high
sensitivity and selectivity that is inherent to mass-
spectrometric detection, while retaining the biological
specificity that is typical for commonly used plate reader
assays.
The use of MS has a number of consequences when MS
is used as analytical tool for readout of bioassays. A
positive implication is the fact that no labels are required in
MS. This widens the application area for these methods,
including target proteins for which no label is available or
can be developed. A second advantage is that the mass
spectrometer measures the actual compounds that have
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Since protein selection methods provide simultaneous
biological and structural data on the compound(s) to be
analyzed, the detection of false positives due to library
impurities or degradation of compounds in a bioactive
mixture is very improbable. A common drawback of using
MS is that bioassay conditions (e.g., buffer used, pH,
blocking reagents, detergents) have to be adjusted to create
MS compatibility. Therefore, usually a compromise is
made, resulting in less favorable MS and bioassay
conditions.
In this review, a comprehensive overview of recent
developments in the field of protein affinity selection
methods that utilize MS is provided. Methods such as
frontal affinity chromatography (FAC) [1], size-exclusion
chromatography (SEC) [2], (pulsed) ultrafiltration [3],
immobilized or dynamic protein affinity selection [4], and
surface plasmon resonance (SPR) coupled with MS [5] can
be named in this regard. The scope is limited to methods
that involve a step that separates bound and unbound
protein before detection of bioactives (ligands). All these
methods consist of the same four steps: (1) complexation of
the protein and test ligand, (2) separation of nonbound
compounds from the protein–ligand mixture, (3) elution/
dissociation, resulting in the release of the free ligand, and
(4) detection of the eluted ligand by MS.
Affinity chromatography
Affinity chromatography is a process in which a protein
(e.g., an antibody), small molecule, or other bioactive agent
is immobilized on a solid support. When a mixture is
injected onto the column containing this solid support,
analytes that show affinity are retained. The method
originates from the late 1960s, when it was used to extract
and purify enzymes [6] or antibodies [7]. The method was
based upon solid supports consisting of mainly sepharose
or agarose. These materials were known for their low
nonspecific adsorptive properties, and their relative ease of
modification, allowing easy immobilization of the desired
target. However, when the method was developed toward
affinity chromatography with the aim of not only extracting
and purifying the analytes, but also ranking them according
to their affinity, it became a necessity to use support
materials that were better equipped for the flow rates and
capillary pressures that are common in high-performance
liquid chromatography (HPLC). The use of pressure-
resistant solid supports is often referred to as the defining
advantage of high-performance affinity chromatography
over conventional affinity chromatography, and was a
starting point for rapid expansion of the number of
applications reported in this field [8]. Two main approaches
are in current use [9]. Firstly, FAC, in which a known
concentration of analyte is infused onto an immobilized
protein column, and the affinity is calculated on the basis of
the saturation time and the shape of the breakthrough curve.
The second is zonal elution, in which the analyte is injected
onto the column together with a competitor. By varying the
concentration of the competitor and measuring the retention
time of the analyte, one can calculate its affinity.
Frontal affinity chromatography
The concept of FAC is more complicated than it appears at
first sight. The target, often a receptor, is (covalently)
immobilized on a column. An analyte is then infused at a
known concentration, and the concentration of the analyte
exiting the column is measured. At the beginning this
amount will be very low, because there is a large amount of
free receptor for the analyte to bind to. However, as a larger
fraction of the immobilized receptor is bound, the amount
of analyte being measured will slowly increase. At some
point, the column will be saturated and the signal in the
detector will equal that of the infused analyte concentration.
The speed at which this happens is dependent on the
association (kon) and dissociation (koff) constants of the
receptor–analyte interaction, which can be calculated by
varying the concentration of the analyte. A schematic
representation of the chromatographic process and the
analytical results is given in Fig. 1.
When developing a FAC method, the handbook of
affinity chromatography by Hage [8] and the paper on
practical protocol development by Ng et al. [10]s h o u l d
provide all the theoretical and practical background
required. Current developments focus on solid support
improvement to facilitate protein immobilization, reduce
nonspecific binding, and stabilize certain classes of target
proteins, and the miniaturization of the protein affinity
column. Prime examples are the use of immobilized
artificial membranes (IAMs) and monolithic affinity
columns.
A significant development in the field of solid supports
is the use of IAMs to form immobilized receptor columns.
Ever since the introduction of FAC in conventional HPLC
systems, target proteins have been immobilized mainly on
silica, glass, or polystyrene, often resulting in the loss of a
major part of their activity. To widen the applicability of
FAC, a solid support contributing to protein stability was
required. IAMs consisting of silica beads covered with
membrane lipids to be used as a stationary phase were
developed by Pidgeon and Venkataram [11] in 1989. In
recent years Beigi et al. [12, 13] have shown the
immobilization of G-protein-coupled receptors (GPCRs),
whereas Temporini et al. [14] have immobilized the orphan
receptor GPR17 on an IAM. Later, this IAM was applied
by Calleri et al. [15] for characterization of ligands. For the
2670 N. Jonker et al.study of multidrug transporters, IAMs were applied to the
determination of known ligands, for which the enantiose-
lectivity and IC50 values could be determined [16].
Moaddel and Wainer [17] provided a comprehensive
guide on IAM development and preparation, allowing fast
implementation by groups with little experience in the field.
In the case of ligand-gated ion channels, one study
describes use of immobilized nicotinic acetylcholine recep-
tors (nAChRs) on IAMs [18]. Similar techniques have been
used that allow the efficient screening of bioactive
mixtures, in some cases allowing hit ranking [19–21]. A
good review describes the potential of FAC-MS for
screening mixtures against immobilized target proteins
and illustrates this with nice examples of pharmaceutical
interest [22]. Xuan et al. [23] looked at the interactions of
the drug carbamazepine with α1-acid glycoprotein to study
relevant drug–plasma protein binding. By changing the
temperature, the authors could elucidate that enthalpy was
the main driving force in the binding interactions. Similar
work studied human serum albumin (HSA) for plasma
protein–drug binding [24], where equilibrium constants
could be estimated for several drugs tested. For other
(sulfonylurea) drugs, similar studies were performed
recently in frontal and zonal modes to obtain information
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Fig. 1 Frontal affinity chromatography (FAC) 1 a compound or
mixture is continuously infused onto an affinity column (2). The
column (backbone) material that is immobilized with target protein,
such as a receptor, retains compounds with affinity. 3 detection of
breakthrough of ligands with mass spectrometry (MS). 4a–7a snap-
shots of the chromatographic breakthrough process of the ligands at
different time points during a FAC analysis. 4b–7b corresponding
detection of breakthrough events with MS per ligand. At full
breakthrough, the infused ligand concentration equals the eluted
concentration
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of affinity microcolumns for the rapid analysis of warfarin
and L-tryptophan for binding of the drug to HSA yielded
data of a kind similar to that in the previous two
conventional bore column examples [26].
Columns in microfluidic chips or in nano liquid chroma-
tography (LC) mode have very low protein consumption
owing to their dimensions. Because these small columns are
hard to pack with conventional bead-type materials, they
have been a prominent target for the development of
monolithic affinity columns. A very elegant method was
reportedby Sharma etal. [19], who immobilized membrane-
bound nAChRs from Torpedo californica in a monolithic
column from diglycerylsilane polymers. By adding the right
amount of poly(ethylene glycol), they wholly incorporated
the membrane and the active receptor in a silica monolith.
Okanda and El Rassi [27] reported a monolithic silica
column with incorporated lectins for affinity ranking in
both nano-LC and capillary electrophoresis (CE).
Zonal affinity chromatography
Zonal elution is a straightforward method of performing
affinity chromatography. Basically it is a classic competi-
tion experiment, implemented in a HPLC system. A known
amount of analyte (or a mixture) is injected onto the affinity
column, in the addition of a competitor. A schematic
representation of the chromatographic process and the
analytical results is given in Fig. 2. As depicted in the
figure, relatively low affinity compounds are eluted as they
are already eluted without the infusion of a competitor.
When a series of experiments is performed using a differing
concentration of competitor, the retention time of the
analyte will vary. Higher concentrations of competitor
result in lower analyte retention times since the competitor
also binds to the affinity column. An advantage of this
method is the low consumption of analyte. However,
developments in affinity chromatography are focused on
frontal analysis as it provides more information per
experiment. Zonal elution is nowadays more often used as
a means to acquire additional data on an interaction
observed in frontal analysis, such as the location of a
binding site [28]. One of the recently published methods
based solely on zonal elution was developed by Bertucci
et al. [29], who investigated the dynamics of the binding
of HIV protease inhibitors to HSA. In another study using
a special kind of column-switching approach, zonal
affinity chromatography was coupled via heart cutting
and used to screen extracts of Coptidis rhizoma for β2-
adrenoceptor affinity [30].
In conclusion, FAC is a prominent technique in
pharmaceutical research because of the high data density
and variety of targets that can be immobilized, such as
GPCRs. Owing to the fast development of frontal analysis,
zonal elution is used more for measurement of additional
binding information. When looking at frontal analysis, one
must address three drawbacks. First, extended controls must
be performed to validate the functionality of the protein
since immobilization influences the freedom of movement
and accessibility of binding sites. Second, immobilized
protein columns have a limited stability and memory effects
from high-affinity ligands or reactive compounds might
compromise column performance. Third, it can be chal-
lenging to produce functionally equal columns.
Affinity selection—binding to immobilized targets
Affinity selection methods, also known as affinity capture
or affinity trapping methods, are similar to affinity
chromatography in the sense that their mechanism of action
depends on possible binding of analytes to immobilized
proteins on a solid support. However, in affinity selection
no chromatographic separation of ligands is involved. The
conditions in which the binding occurs are optimized to
stabilize the protein–analyte complex, wash off nonbinders,
and then dissociate the complex to detect the binding
analytes. To identify binders, most of these methods
employ mass-spectrometric detection. Because the com-
pounds are not separated on the basis of their affinity for
the receptor, the resulting analytes cannot be ranked, but
can only be grouped in binders and nonbinders. Optimizing
the threshold to distinguish these two groups, to eliminate
false negatives and limit false positives, is one of the most
challenging aspects of affinity selection development.
Although affinity selection in one form or another has
been around for decades [31–33], it became more promi-
nent in bioanalysis upon the introduction of the lectin-based
affinity materials, used to extract bacteria and carbohy-
drates with a specific binding motif for matrix-assisted laser
desorption ionization (MALDI) time-of-flight (TOF) anal-
ysis [34, 35]. These methods allowed detection of target
proteins that are difficult to analyze in any conventional
way owing to the complex matrices they are in. Since that
time, a number of specific affinity materials have been
developed with considerable success. Krugman et al. [36]
presented their work in which a novel family of proteins
found in leukocytes bound specifically to phosphoinositide
affinity material. Kong at al. [37] described a diamond-
based affinity material with the property of extracting
proteins from complex mixtures with MALDI-TOF analy-
sis. Recently, Ferrance [4] has shown the feasibility of
immobilizing proteins on gellan (a polysaccharide) beads.
The optical transparency of these beads allows direct
measurement of the amount of protein successfully immo-
bilized on the material.
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comprises a large number of methods similar to protein
affinity chromatography, but with the difference that it
separates proteins, small organic ligands, or phosphopep-
tides on the basis of their affinity. Instead of protein–ligand
affinity, metal–protein (or metal–ligand) affinity is deter-
mined. For proteins, the affinity mainly depends on the
number and location of histidine residues in the proteins to
be analyzed, and to a lesser extent on cysteine and
tryptophan residues [38]. When a protein is His-tagged, a
very high affinity between the His-tag and the immobilized
metal ion efficiently traps any His-tagged protein. Jonker et
al. [39] utilized this principle by trapping an in-solution-
formed His-tagged protein–ligand complex on a small
nickel-loaded column. This allows ligand–protein complex
formation in solution, using the immobilized metal column
merely to separate the bound and unbound fractions,
followed by release of the ligands from the trapped proteins
for mass-spectrometric detection. Figure 3 shows a sche-
matic view of the analytical setup. Another variant of
affinity capture methods is ligand fishing using magnetic
particles. For this so-called magnetic bead dynamic protein
affinity selection, IMAC coated magnetic beads are used to
trap a His-tagged protein–ligand complex from a sample for
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Fig. 2 Zonal affinity chromatography (ZAC) 1 a compound or
mixture is injected onto an affinity column (2). The column
(backbone) material that is immobilized with target protein, such as
a receptor, retains compounds with affinity. 3 detection of eluted
ligands with MS as peaks in the MS trace. 4a–7a snapshots of eluted
ligands at different time points during a ZAC analysis. 4b–7b
corresponding detection of ligand elution events with MS per ligand.
When high-affinity ligands are to be analyzed, continuous infusion of
a competitor is necessary to prevent extremely long retention times
Recent developments in protein–ligand affinity mass spectrometry 2673further processing and final MS [40]. Figure 4 shows a
schematic representation of the ligand trapping process. In
other examples, Marsza et al. [41] employed magnetic
beads coated with heat shock protein for ligand fishing,
whereas Hu et al. [42] reported an enzyme inhibition
screening assay utilizing enzymes immobilized on magnetic
beads.
In conclusion, the advantage of affinity selection
methods is the wide applicability, the easy compensation
that can be made for nonspecific binding, and their
relatively high sensitivity. The major drawback is the fact
that affinity ranking is not possible using these methods.
The analytical results of these methods will be a group of
binders and a group of nonbinders. The biggest challenge is
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Fig. 3 Dynamicproteinaffinitychromatographicsystem.Theupper-left
part comprises an online Ni
2+ stripping pump with EDTA and a Ni
2+
regeneration pump, both connected via a switch valve. The Ni
2+-
iminodiacetic acid (Ni-IDA) trapping column is able to retain His-tagged
proteins. The lower-left part consists of a switch valve for selecting
wash, equilibration, and disruption (of ligands bound to immobilized
target protein) procedures via the liquid chromatography (LC)p u m p s
connected. The solid-phase extraction (SPE) column traps disrupted
ligands from the Ni-IDA column prior to gradient LC-MS
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Fig. 4 The dynamic trapping process of magnetic beads in high-
performance LC [poly(ether ether ketone)] tubing. 1 injected plug of a
bioactive compound mixture incubated with target protein and (para)
magnetic beads flows through the LC tubing and arrives at the
external magnet placed near the tubing. 2 beads with immobilized
target protein and ligands (bound to the target protein) are retained in
the magnetic field. Nonbinders are eluted to waste. 3 An eluent switch
disrupts the target protein–ligand complex and allows ligands to be
eluted. A post-magnetic field switch valve directs ligands to SPE for
further analysis. 4 automated repositioning of the magnet away from
the LC tubing allows the beads to go to waste (after switching the
switch valve again)
2674 N. Jonker et al.to eliminate false negatives, and limit false positives as
much as possible.
Affinity selection—binding to targets in solution
Separation by ultrafiltration
Traditional ultrafiltration
In the early 1980s, ultrafiltration was developed as a
means to measure protein–ligand interactions in solution-
based complexes [43, 44]. The concept of the technique is
rather straightforward. A certain amount of pressure is
applied to an amount of liquid containing protein–ligand
complexes as well as free ligand and protein. This can be
achieved by applying pressure using a pump, vacuum, or
centrifugal force. The ultrafiltration unit contains a
molecular weight cutoff membrane, allowing solvents
and nonbound small molecules to pass through, but
retaining proteins and protein–ligand complexes. This
achieves effective separation of the bound and nonbound
fractions of the analyte, allowing detection of the bound
ligand by any available detection method. The huge
advantage of this method over other existing methods is
that complex formation takes place in solution, allowing
the protein the same degree of freedom it would have in
vivo.
A number of groups have developed methods using
continuous ultrafiltration [45, 46]. In this technique, a fixed
amount of protein is injected into an ultrafiltration chamber
and the analyte is then pumped through the chamber. Fung
et al. [47] were among the first to automate ultrafiltration
for high-throughput analysis. Some other recent publica-
tions include the work of Comess et al. [48], who
developed a high-throughput serial ultrafiltration method
to screen a library of compounds for affinity for a
pharmacologically relevant streptococcal enzyme. Finally,
Li et al. [49] developed an online-coupled ultrafiltration–
LC-MS method that was used to screen natural extracts for
α-glucosidase inhibitors.
Some very recent examples include the quantification of
unbound prednisolone, prednisone, cortisol, and cortisone
in human plasma by ultrafiltration–LC-MS [50] and the
development of an ultrafiltration–LC-MS-based ligand-
binding assay for Mycobacterium tuberculosis shikimate
kinase [51], to be used for the development of antimicrobial
agents. For screening of potential lead compounds in
malaria drug discovery, work was performed for the drug
targets Plasmodium falciparum thioredoxin and glutathione
reductases [52]. Another study used ultrafiltration-based
affinity selection MS for the kinase Chk1 involved in DNA
damage [53]. A slightly different example employed
hollow-fiber membranes coupled online to a MS system
for continuous affinity selection [54].
Pulsed ultrafiltration
The development of pulsed ultrafiltration by van Breemen
et al. [55] significantly increased the applicability of
ultrafiltration. Instead of filtration of an entire sample, a
small amount of sample was injected into the ultrafiltration
unit. The liquid flow pushes the nonbound fraction through
the molecular weight cutoff membrane, to waste. After-
wards, the bound ligand is dissociated from the protein by
buffer adjustment. The formerly bound fraction is then
pushed through the membrane, and immediately measured
and identified by MS. Figure 5 illustrates this process. The
two main advantages over traditional ultrafiltration are that
(1) less analyte is needed and (2) target proteins can be
reused if a nondestructive dissociation buffer is applied.
The method could be applied to complex mixtures as well
as combinatorial libraries, and it functioned online, was
automated, and was suitable for high-throughput screening.
Since the publication of this method, most ultrafiltration
applications have used some or all of the characteristics of
pulsed ultrafiltration, very often without identifying them as
such. As a result, there no longer exists a strict division
between traditional and pulsed ultrafiltration. The technol-
ogy and terminology involved are very often used incor-
rectly. However, a significant number of interesting
advancements has been reported since. Some successful
applications of pulsed ultrafiltration include its use by the
group of van Breemen to study metabolic stability [56],
inhibitors of protein aggregation [57], and ligands for
human retinoid X receptor α [58]. In the field of
ultrafiltration, most developments are focused on new
applications, and not on improving the technology. The
latest development was also by the group of van Breemen
and involved the discovery of cyclooxygenase inhibitors
from medicinal plants used to treat inflammation [59].
When reviewing ultrafiltration, it is apparent that two
advantages of ultrafiltration-based affinity selection meth-
ods are (1) in-solution complex formation and (2) the
possibility to reuse the target protein.
Separation by size-exclusion chromatography
The concept of separating compounds by size was
developed in the 1960s in the form of gel permeation
chromatography, mainly applied to the analysis of high
molecular weight polymers [60]. The concept is as simple
as it is elegant. A cross-linked dextran gel is used as the
column material. The porosity of the gel determines its
separation properties, resulting in less retention for larger
molecules, and more retention for smaller molecules. This
Recent developments in protein–ligand affinity mass spectrometry 2675is caused by diffusion of the smaller molecules into pores in
the polymeric gel. Because small molecules can enter these
pores and the larger ones (proteins) can not, their retention
time is longer. With the development of more advanced
gels and other size-exclusion materials, the separation
power of size-exclusion-based methods has steadily
increased since their inception. Size-exclusion methods
are easy to automate and very suitable for implementation
in screening assays. While the columns used can be placed
online or used off-line in high-throughput fashion (e.g.,
adapted to 96-well plates), other variants, such as spin-
column-based methods, have also been used [61].
A direct successor to classic gel permeation chromatog-
raphy is the SpeedScreen technology [2]. It consists of a
double 96-well plate format. The upper part contains a size-
exclusion gel, and has holes in the bottom of the plate. An
in-solution protein–ligand incubation mixture is pipetted on
top of the gel, and this is placed upon the second plate, a
collection plate. The incubate is separated owing to
centrifugal force, and bound and unbound ligands are
separated. The 96-well plate is then analyzed using a
LC-MS system. The system screens one 96-well plate
within 10 min, has routinely been applied by Novartis, and
has resulted in a number of lead compounds [62].
1 1
3
6
5
4
2
Inject sample, Inject sample,
Wash non-binder Wash non-binders
W
Switch from Waste to Switch from Waste to
MS when non-binders MS when non-binders
have elute have eluted
Use disruption eluen Use disruption eluent
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Fig. 5 Pulsed ultrafiltration chromatography. 1 mixture with ligands
and nonbinders injected into an ultrafiltration chamber. Ligands (blue)
bind to target protein (2) that is retained in the upper part of the
chamber (3) separated from the bottom part (4) by a membrane that is
not permeable for large proteins. Small-molecule nonbinders can
diffuse through the membrane and be eluted to the waste (W) via
continuously infused (MS-compatible) buffer (5). When the mixture is
injected and during the washing of nonbinders, a buffer is infused that
allows target protein–ligand binding (6). During the ligand-disruption
step for ligand elution to MS (7), the bottom part of the chamber is
switched from the waste to MS and a disruption buffer is infused via 6
into the upper chamber
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columns are being used in almost all branches of protein
analysis. A much larger variety of materials is available in
SEC than in gel permeation chromatography (which
traditionally uses Sephadex gels), and the reusability of
these materials allows the use of such columns in online LC
methods. In 2004, Neogenesis developed an automated
high-throughput-screening assay using online SEC coupled
with MS for the assessment of protein–ligand interactions
[63]. This method, named automated ligand identification
system (ALIS), uses a standardized SEC-LC-MS setup, but
contains an in-house-developed resin as the size-exclusion
material. The fast affinity screening results included the
discovery of a lipid phosphatase inhibitor involved in type
2 diabetes [64]. Characterization of orthosteric and alloste-
ric ligands for the muscarinic M-2 acetylcholine receptor
was also feasible with the system [65]. Furthermore,
Whitehurst and Annis [66] described affinity selection
methods and their emerging role for screening GPCR
ligands.
Following the success of ALIS, a number of groups
developed innovative applications for size-exclusion affin-
ity measurements. Flarakos et al. [67] developed a method
able to assess and rank ligand binding to HSA based on
automated SEC coupled online to a two-dimensional
LC-MS system. Binding of ligands to Akt-1 and Zap-70
kinases, the muscarinic acetylcholine receptor M2 [68], or
the histamine H2 receptor [69] followed by SEC-based
purification of the receptor–ligands and disruption for
release of ligands to MS was performed by Annis et al.
[68] and Derks et al. [69], respectively.
Separation by filtration or centrifugation
A method similar to that used in the work by Annis et al.
[68] and Derks et al. [69] used a native marker ligand for,
e.g., the dopamine D2 receptor, thereby allowing the
analysis of ligand binding to GPCRs after a rapid solid-
phase extraction MS step [70, 71]. A followup technology
used MALDI as an ionization source. This adaptation
allowed a large throughput increase owing to rapid analysis
of the eventually spotted 96-sample MALDI plates [72].
Slightly different approaches use a rapid filtration step (in
96-filtration well plates) instead of SEC to obtain the same
assay principle. Here, a native marker ligand is measured
with MS after the filtration step [73]. A typical workflow of
this setup is depicted in Fig. 6. The technology is actually
more based on traditional radioligand binding assays in
which the bound marker ligand is now not analyzed by the
radioactivity of the marker, but by its molecular mass. The
advantages here are the universal applicability (for most
receptors the native ligand is available) and elimination of
the need for a radiolabeled ligand. A slight variation on this
theme is the use of short reversed-phase C18 columns using
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Fig. 6 The principle of MS binding assays (e.g., SpeedScreen).
Ligands, target protein, and tracer/target ligand in a 96-well plate (1)
are aspirated (2) and subsequently dispensed onto a 96-well filtration
plate (3). After washing of the filtration plate (4) to remove
nonbinders, methanol is added (5) to allow disruption and elution of
binders (6) to another 96-well plate (7) for measurement by LC-MS
(8). Quantification of the tracer/target ligand by triple-quadrupole MS
allows determination of the percentage of tracer/target ligand
displacement by unknown ligand binders
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MS binding assays [74].
Concluding, SEC coupled with MS is a very powerful
method with wide applicability, easy automation, and
proven results in both fundamental research and screening
applications. Its disadvantages are nonspecific binding to
the size-exclusion material, which can result in false
positives or negatives, and that reusability of the columns
is significantly reduced when more complex protein
matrices are researched.
Affinity capillary electrophoresis
CE has been used for the separation of proteins and
peptides for several decades; however, in the 1990s several
groups developed methods to assess protein–ligand inter-
actions [75], peptide–antibiotic binding [76], or protein–
DNA binding [77] using capillary zone electrophoresis.
Since then, the field of affinity CE (ACE) has gradually
expanded and increased its applicability [78, 79]. Two
major technological breakthroughs have contributed to the
development of modern-day ACE: coupling with MS and
the use of microfluidic chip technology. When focusing on
protein–drug interactions, one needs to separate ACE
methods into two categories: mobility shift methods and
immobilized protein methods.
Mobility shift methods
In mobility shift methods, the protein and ligand form a
noncovalent complex in solution. For compounds with a
very slow koff, a small amount of this incubation mixture
is injected into a standard CE-MS system, and the
constituents of the mixture are separated on the basis of
the fact that the noncovalent protein–ligand complex has
an electrophoretic mobility distinctly different from that of
the nonbound protein and ligand. The concentration of the
bound and nonbound fractions can be quantified using
MS, and protein–ligand affinity can be calculated from
these results. An interesting example was reported by
Groesll et al. [80] coupling CE with inductively coupled
plasma MS. This enabled the researchers to assess binding
between gallium(III)-based anticancer drugs and serum
proteins.
In the case of protein–ligand complexes with a fast koff,t h e
complex will dissociate quickly upon injection into the CE-
MS system. In these cases, either the ligand or the protein
will be added to the electrophoresis buffer, thus changing the
mobility of its counterpart in the capillary. Many varieties of
mobility shift methods have been developed and a frequently
used variant is frontal analysis CE (FACE), distinctly
different from FAC in the fact that the protein is not
immobilized on a solid support, but is incubated with a
ligand before injection. Recently, Fermas et al. [81]
developed a method aimed at the study of complexation
between antithrombin and heparin pentasaccharide. They
combined a continuous infusion of a preincubated protein–
ligand complex solution with mass-spectrometric detection.
Since the development of FACE, it has become apparent it
can be used to determine protein–ligand affinity for a great
variety of targets and libraries. A small number of examples
published in 2009 and 2010 are the interaction between
lidocaine and hyaluronic acid [82], the interaction between a
large number of drugs and the human liposome [83], and
affinity studies performed on a large test set of drugs and
HSA [84]. Many similar drug–protein binding studies
have been performed, all providing precise and sensitive
binding data [85]. In some cases, this technology allows
albumin to act as a chiral selector owing to its many drug–
protein binding characteristics [86]. Other recent examples
allow the receptor affinity analysis of bioactive inflam-
matory cytokines present in skin biopsies in a chip-based
CE system [87].
Immobilized protein methods
Immobilized protein methods involve any method in which
the target protein is immobilized on a solid support, be it
silica, (magnetic) beads, microfluidic chips, or anything
else. When a sample containing one or more possible
ligands to the target protein is injected into the system, the
ligand(s) will bind to the immobilized target protein, thus
facilitating sample cleanup, preconcentration, or performing
a buffer change before detection. In the past couple of
years, these methods have increased in relevance owing to
the relative ease of immobilizing protein on microfluidic
chips and magnetic beads. Yang et al. [88] reported an
immunoaffinity CE method incorporating an anti-α-
fetoprotein column inside a microfluidic chip allowing
automated detection of early stage cancer diagnostic α-
fetoprotein. Xiao et al. [89] have provided a proof-of-
principle using a microfluidic chip with immobilized
strands of DNA on it, able to selectively trap insulin and
insulin-like growth factor 2,w i t hs u b s e q u e n tM A L D I -
TOF-MS detection. The recent move toward the use of
magnetic beads in affinity measurements combined with
CE can also lead to interesting results and allows in-
capillary affinity preconcentrations [90, 91]. When assess-
ing the merits of ACE, it is apparent the field has evolved
to a point where it can compete with other affinity
methods described in this article. It is a relatively simple
and straightforward method to implement and use routine-
ly. However, ACE has hurdles to overcome such as
nonspecific adsorption, Joule heating, and the implemen-
tation of mass-spectrometric detection.
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SPR differs fundamentally from all other methods pre-
sented in this review, because protein binding and detection
take place at the same location. A SPR biosensor consists
of a prism positioned against a thin metal layer (often gold)
and a solution at the opposite side of the metal layer. Upon
directing a beam of light onto the surface under different
angles, surface plasmons occur at the interface between the
metal and the solution, which implies that photons excite
electrons in the metal film. At a specific angle of incidence,
the wave vector of these excited electrons is equal to that of
the surface plasmons, resulting in a total energy transfer and
the light beam is no longer reflected. This is the principle of
SPR and when it happens, the light beam is no longer
reflected. SPR is used as a means of detection as it is
dependent on the analytes present in the solution near the
surface. When a ligand binds to a protein immobilized on
the metal sensor, this changes the wave vector of the
surface plasmons, and the angle of incidence at which SPR
occurs, which is detected. However, as the technology only
allows analysis of binding events and no identification
occurs, SPR is nowadays often coupled to a mass
spectrometer to identify the binders.
In the field of small-molecule research, significantly
fewer methods have been reported, presumably owing to
the dependency of the SPR signal on molecular weight and
as a result, its improved performance for analytes above
15 kDa. However, recently Jecklin et al. [92] developed a
SPR method for seven analytes under 500 Da. Utilizing
human carbonanhydrase immobilized on a SPR chip, they
managed to calculate accurate dissociation constants for the
test set, and compared them with those from two reference
methods. Also, Marchesini et al. [93] successfully mea-
sured the binding and dissociation kinetics of a test set of
seven low molecular weight paralytic shellfish poisons
binding to immobilized saxitoxin monoclonal antibody.
Furthermore, recent publications by Wang et al. [94]a n d
Miura et al. [95] show the development of indirect SPR
affinity methods, in which the affinity of a small molecule is
determined by its competition with a large ligand already
bound to the immobilized target protein. Concluding, SPR is
most efficient for compounds with a high molecular weight,
but developments that target small molecules are upcoming.
Conclusion
Reviewing the wide spectrum of methods discussed in this
paper for protein–ligand affinity interactions, we can
separate all of them into two general categories. The first
group consists of methods that immobilize the target
protein on a solid support, whereas the second group of
these methods allow in-solution complexation. Ultrafiltra-
tion and size exclusion are solution-based methods. The
complexisformedinsolution,approachinginvitroconditions
as closely as possible. The same applies for dynamic protein
affinity selection and a number of CE methods. All other
techniques, frontal affinity, zonal elution, affinity capture, and
most CE-based methods, use immobilized proteins. When
assessing the progress made using immobilized proteins, we
can draw a number of conclusions. FAC will remain relevant,
because it is a cheap and easy-to-implement method to assess
protein–ligand binding. The immobilized target proteins are
becoming more and more complex in terms of their instability
and the environment needed to maintain their activity, and
none of the in-solution-based methods rival the data resulting
from FAC methods.
The solution-based methods might not provide the same
amount of affinity data, but they do not suffer from impaired
binding properties due to protein immobilization, and each of
them has advantages of its own. Ultrafiltration benefits from
the reusability of the receptor, and the speed of measurement.
CE affinity selection can target proteins unsuitable for any of
the other methods, and will stay important despite issues with
nonspecific absorption of the proteins to the capillary walls
and MS compatibility. The size-exclusion methods are the
ones most commonly applied in modern drug discovery for
two simple reasons. SEC is very easy to implement and
automate using standard 96-well plates and equipment, and it
is significantly faster than all the other techniques discussed.
SPR-MS is limited by its inability to measure small ligands
conveniently, but advances in life sciences allow more and
more target proteins to be used to study them for small-
molecule binding interactions. Furthermore, a limited number
of target proteins have been successfully immobilized on the
SPR chip, but this number is steadily increasing. Finally, care
mustbetaken thatSPRcoupled withMSisnot usedjustasan
expensive affinity selection device since the main strength of
SPR is analysis of binding kinetics, which is only possible
when studying single known compounds, whereas the
strength of (LC-)MS is the analysis of unknown compounds
in mixtures.
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